Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Zengun in connection with its issuance of sustainability-linked bonds and a tender offer
Mandate

Vinge advises Zengun in connection with its issuance of sustainability-linked bonds and a tender offer

February 05, 2024 Banking and Finance

Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured sustainability-linked bonds in an amount of SEK 400 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued bonds due 2024. The bonds are intended to be listed on the sustainable bond list of Nasdaq Stockholm. The bonds have a tenor of four years and were issued with a coupon of STIBOR 3m + 635 basis points.

Carnegie Investment Bank AB (publ) acted as global coordinator, joint bookrunner and dealer manager, and Nordea Bank Abp acted as joint bookrunner and dealer manager in the transaction.

 

Vinge’s team consisted of Magnus Pauli, Lionardo Ojeda, Arvid Weimers and Malin Waldén.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025